TRC-051384
CAS No. 867164-40-7
TRC-051384( TRC051384 )
Catalog No. M16303 CAS No. 867164-40-7
A potent heat shock protein 70 (HSP70) inducer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 58 | Get Quote |
|
| 5MG | 91 | Get Quote |
|
| 10MG | 164 | Get Quote |
|
| 25MG | 339 | Get Quote |
|
| 50MG | 497 | Get Quote |
|
| 100MG | 708 | Get Quote |
|
| 200MG | 963 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTRC-051384
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent heat shock protein 70 (HSP70) inducer.
-
DescriptionA potent heat shock protein 70 (HSP70) inducer, involves HSF1 activation; significantly reduces stroke associated neuronal injury and disability in a rat model of transient ischemic stroke; delays thrombus formation without increased bleeding risk in mice.
-
In VitroTRC051384, dose dependently induces HSP70B mRNA by several hundred folds in both HeLa and rat primary mixed neurons. Treatment with TRC051384 results in significant dose-dependent increase in HSF1 transcriptional activity and recovery of luciferase activity. TRC051384 results in 60% inhibition at 6.25 μM and 90% inhibition at 12.5 μM of LPS-induced TNF-α expression in differentiated THP-1 cell line.
-
In VivoTreatment with TRC051384 significantly reduces stroke associated neuronal injury (87% reduction in area of penumbra recruited to infarct, and 25% reduction in brain edema) and disability in a rat model of transient ischemic stroke even when administered 8 hours post onset of ischemia. Significant improvement in survival (50% by day2 and 67.3% by day 7) is observed with TRC051384 treatment initiated at 4 hours after ischemia onset. Induction of HSP70 by TRC051384 involves HSF1 activation and results in elevated chaperone and anti-inflammatory activity.
-
SynonymsTRC051384
-
PathwayCytoskeleton/Cell Adhesion Molecules
-
TargetHSP
-
RecptorHSP70
-
Research AreaMetabolic Disease
-
Indication——
Chemical Information
-
CAS Number867164-40-7
-
Formula Weight465.54
-
Molecular FormulaC25H31N5O4
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥100 mg/mL
-
SMILESO=C(NC1=CC=C(C(/C=C/C2=NC(N3CCOCC3)=CC=C2)=O)C=C1)NCCN4CCOCC4
-
Chemical NameUrea, N-[2-(4-morpholinyl)ethyl]-N'-[4-[3-[6-(4-morpholinyl)-2-pyridinyl]-1-oxo-2-propen-1-yl]phenyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mohanan A, et al. Neuropharmacology. 2011 May;60(6):991-9.
2. Allende M, et al. Cardiovasc Res. 2016 Jun 1;110(3):309-18.
molnova catalog
related products
-
KU675
A novel, second-generation C-terminal Hsp90 inhibitor with Kd of 191 and 726 uM for Hsp90α and Hsp90β, respectively.
-
CP-9
A potent Hsp90α/p23 interaction inhibitor with IC50 of 3.2 uM; 5-fold less potent for Hsp90β/p23 interaction (IC50=15.3 uM).
-
KBU2046
KBU2046 (KBU-2046) is a highly selective inhibitor of metastasis, binds to and stabilizes CDC37/HSP90β heterocomplexes.
Cart
sales@molnova.com